[Skip to Content]
[Skip to Content Landing]
Article
March 1994

Prevention of Experimental Proliferative Vitreoretinopathy With a Biodegradable Intravitreal Implant for the Sustained Release of Fluorouracil

Author Affiliations

From the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami (Fla) School of Medicine. None of the authors has a proprietary interest in the polymer implants described herein.

Arch Ophthalmol. 1994;112(3):407-413. doi:10.1001/archopht.1994.01090150137036
Abstract

Objective:  To test the efficacy of a biodegradable device for the intravitreal sustained release of fluorouracil in the treatment of tractional retinal detachment due to proliferative vitreoretinopathy.

Methods:  A6×0.9-mm (20-gauge) cylindrical solid implant molded from copolymers of lactide and glycolide admixed with 1 mg of fluorouracil was placed in the vitreous cavity of rabbits in which retinal detachment with proliferative vitreoretinopathy had been initiated. Comparisons of the control (drug-free polymer) and experimental (fluorouracil polymer) groups were made with weekly indirect ophthalmoscopic examinations. In another experiment, the intravitreal concentration of fluorouracil was tested at each time point.

Results:  Retinas of eight (89%) of nine rabbits that received the polymer with fluorouracil remained attached compared with only one animal (11%) that received the control polymer without the drug. The therapeutic effect of the drug-containing implant was associated with sustained intravitreal concentrations of fluorouracil between 1 and 13 mg/L for at least 14 days, and fluorouracil concentrations remained above 0.3 μg/mL for almost 21 days. No evidence of the toxic effects of the drug or polymer implant was observed with electroretinographic and histopathologic study.

Conclusion:  Intravitreal implantation of biodegradable polymers containing fluorouracil can prevent proliferation of epiretinal membranes resulting in complicated retinal detachment in an animal model of proliferative vitreoretinopathy and indicate their possible usefulness for intravitreal delivery of therapeutic agents.

References
1.
The Retina Society Terminology Committee.  The classification of retinal detachment with proliferative vitreoretinopathy . Ophthalmology . 1983;90:121-125.Article
2.
The Silicone Study Group.  Proliferative vitreoretinopathy . Am J Ophthalmol . 1985;99:593-595.
3.
Brinton GS, Aaberg TM, Reeser FH, Topping TM, Abrams GW.  Surgical results in ocular trauma involving the posterior segment . Am J Ophthalmol . 1982;93:271-278.
4.
Lewis H, Aaberg TM, Abrams GW.  Causes of failure after initial vitreoretinal surgery for severe proliferative vitreoretinopathy . Am J Ophthalmol . 1991;111:8-14.
5.
Lewis H, Aaberg TM.  Causes of failure after repeat vitreoretinal surgery for recurrent proliferative vitreoretinopathy . Am J Ophthalmol . 1991;111:15-19.
6.
Blumenkranz M, Hernandez E, Ophir A, Norton EWD.  5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite . Ophthalmology . 1984;91:122-130.Article
7.
Blumenkranz MS, Ophir A, Claflin AJ, Hajek A.  Fluorouracil for the treatment of massive periretinal proliferation . Am J Ophthalmol . 1982;94:458-467.
8.
Stern WH, Lewis GP, Erickson PA, et al.  Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy . Am J Ophthalmol . 1983;96:33-42.
9.
Tano Y, Sugita G, Abrams G, Machemer R.  Inhibition of intraocular proliferation with intravitreal corticosteroids . Am J Ophthalmol . 1983;96:131-136.
10.
Chandler DB, Rozakis G, de Juan E, Machemer R.  The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy . Am J Ophthalmol . 1985;99:686-690.
11.
Kirmani M, Santana M, Sorgente N, Wiedemann P, Ryan SJ.  Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy: control by daunomycin . Retina . 1983;3:269-272.Article
12.
Wiedemann P, Lemmen K, Schmiedl R, Heimann K.  Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy . Am J Ophthalmol . 1987;104:10-14.
13.
Jarus G, Blumenkranz M, Hernandez E, Sossi N.  Clearance of intravitreal fluorouracil: normal and aphakic vitrectomized eyes . Ophthalmology . 1985;92:91-96.Article
14.
Villain F, Davis P, Kiss K, Cousins SW, Parel J, Parrish RK.  A bioerodible intraocular implant for controlled drug release of 5-fluorouracil . Invest Ophthalmol Vis Sci . 1992;33( (suppl) ):737. Abstract.
15.
Haimovici R, Yang CM, Hernandez E, Cousins SW.  A new model for rhegmatogenous retinal detachment with proliferative vitreoretinopathy . Invest Ophthalmol Vis Sci . 1991;32( (suppl) ):769. Abstract.
16.
Chandler DB, Quansah FA, Hida T, Machemer R.  A refined experimental model for proliferative vitreoretinopathy . Graefes Arch Clin Exp Ophthalmol . 1986;224:86-91.Article
17.
Jacobsen SG, Kemp CM, Borruat FX, Chaiten MH, Faulkner DJ.  Rhodopsin topography and rod-mediated function in cats with the retinal degeneration of taurine deficiency . Exp Eye Res . 1987;45:481-490.Article
18.
Hartzer MK, Blumenkranz MS.  Fluoropyrimidines in the treatment of proliferative vitreoretinopathy and glaucoma . In: Tso MOM, ed. Retinal Diseases: Biomedical Foundations and Clinical Management . Philadelphia, Pa: JB Lippincott; 1988:347-361.
19.
Hatchell DL, McAdoo T, Sheta S, King RT III, Bartolome JV.  Quantification of cellular proliferation in experimental proliferative vitreoretinopathy . Arch Ophthalmol . 1988;106:669-672.Article
20.
Nao-IN, Honda Y.  Toxic effect of fluorouracil on the rabbit retina . Am J Ophthalmol . 1983;96:641-643.
21.
Liu KR, Peyman GA, Khoobehi B, Alkan H, Fiscella R.  Intravitreal liposome-encapsulated trifluorothymidine in a rabbit model . Ophthalmology . 1987;94:1155-1159.Article
22.
Assil KK, Weinreb RN.  Multivesicular liposomes: sustained release of the antimetabolite cytarabine in the eye . Arch Ophthalmol . 1987;105:400-403.Article
23.
Barza M, Stuart M, Szoka F.  Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes . Invest Ophthalmol Vis Sci . 1987;28:893-900.
24.
Sanborn GE, Anand R, Torti RE, et al.  Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device . Arch Ophthalmol . 1992;110:188-195.Article
25.
Lewis H, Schwartz S, Lee D.  The use of bioerodible polymer and 5-fluorouracil in the treatment of experimental proliferative vitreoretinopathy . Invest Ophthalmol Vis Sci . 1991;32( (suppl) ):1047.
×